41 research outputs found

    Garvicins AG1 and AG2 : two novel class IId bacteriocins of lactococcus garvieae Lg-Granada

    Get PDF
    Funding: This research was funded by the Spanish Ministry of Science, Innovation, and Universities, grant number RTI2018-098530-B-I00. The APC was funded by the Spanish Ministry of Science, Innovation, and Universities, grant number RTI2018-098530-B-I00.Lactococcus garvieae causes infectious diseases in animals and is considered an emerging zoonotic pathogen involved in human clinical conditions. In silico analysis of plasmid pLG50 of L. garvieae Lg-Granada, an isolate from a patient with endocarditis, revealed the presence of two gene clusters (orf 46–47 and orf 48–49), each one encoding a novel putative bacteriocin, i.e., garvicin AG1 (GarAG1; orf 46) and garvicin AG2 (GarAG2; orf 48), and their corresponding immunity proteins (orf 47 and orf 49). The chemically synthesised bacteriocins GarAG1 and GarAG2 presented inhibitory activity against pathogenic L. garvieae strains, with AG2 also being active against Listeria monocytogenes, Listeria ivanovii and Enterococcus faecalis. Genetic organisation, amino acid sequences and antimicrobial activities of GarAG1 and GarAG2 indicate that they belong to linear non-pediocin-like one-peptide class IId bacteriocins. Gram-positive bacteria that were sensitive to GarAG2 were also able to ferment mannose, suggesting that this bacteriocin could use the mannose phosphotransferase transport system (Man-PTS) involved in mannose uptake as a receptor in sensitive strains. Intriguingly, GarAG1 and GarAG2 were highly active against their own host, L. garvieae Lg-Granada, which could be envisaged as a new strategy to combat pathogens via their own weapons.Publisher PDFPeer reviewe

    Garvicins AG1 and AG2:two novel class IId bacteriocins of <i>lactococcus garvieae</i> Lg-Granada

    No full text
    Lactococcus garvieae causes infectious diseases in animals and is considered an emerging zoonotic pathogen involved in human clinical conditions. In silico analysis of plasmid pLG50 of L. garvieae Lg-Granada, an isolate from a patient with endocarditis, revealed the presence of two gene clusters (orf 46–47 and orf 48–49), each one encoding a novel putative bacteriocin, i.e., garvicin AG1 (GarAG1; orf 46) and garvicin AG2 (GarAG2; orf 48), and their corresponding immunity proteins (orf 47 and orf 49). The chemically synthesised bacteriocins GarAG1 and GarAG2 presented inhibitory activity against pathogenic L. garvieae strains, with AG2 also being active against Listeria monocytogenes, Listeria ivanovii and Enterococcus faecalis. Genetic organisation, amino acid sequences and antimicrobial activities of GarAG1 and GarAG2 indicate that they belong to linear non-pediocin-like one-peptide class IId bacteriocins. Gram-positive bacteria that were sensitive to GarAG2 were also able to ferment mannose, suggesting that this bacteriocin could use the mannose phosphotransferase transport system (Man-PTS) involved in mannose uptake as a receptor in sensitive strains. Intriguingly, GarAG1 and GarAG2 were highly active against their own host, L. garvieae Lg-Granada, which could be envisaged as a new strategy to combat pathogens via their own weapons

    Molecular typing of Streptococcus suis isolates from Iberian pigs: A comparison with isolates from common intensively-reared commercial pig breeds

    No full text
    The Iberian pig (IP) is a traditional Spanish breed variety of the domestic pig (. Sus scrofa domesticus) with high economic importance because of the value of the dry-cured products in national and international markets. The genetic characteristics of tonsillar and clinical Streptococcus suis isolates from the IP maintained under extensive or intensive management conditions were investigated. S.-suis isolates from IP pigs were compared with S.-suis isolates from intensively-farmed pigs of common breeds (CBP). S.-suis was isolated from 48.4% of the IP tonsils examined, indicating wide distribution among IP pigs.Serotypes 1 (9.4%), 2 (8.6%) and 9 (7%) were the most commonly found, although a high percentage of S.-suis isolates were not typeable by coagglutination testing. No significant differences in carrier rates or serotype diversity were observed between management systems, indicating that intensive farming does not influence S.-suis colonisation. Both pulsed-field gel electrophoresis and multiple-locus variable number tandem repeat analysis showed a serotype-based distribution of S.-suis IP isolates. Serotypes 1 and 2 S.-suis isolates were grouped in the same cluster, whereas isolates of serotypes 9 and 7 were assigned to another cluster. All clinical and most tonsillar serotype 2 IP isolates were assigned to sequence type 1 (ST1) and exhibited the virulence genotype mrp+/epf+/sly+, indicating a high distribution of this genetic lineage among IP as well as a population of serotype 2 common to IPs and CBPs. The only clinical isolate of serotype 9 from IP was assigned to ST123, a sequence type associated with clinical isolates in CBPs in Spain. © 2014 Elsevier Ltd
    corecore